Article
A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
Biochemical and biophysical research communications - 7 Dec 2012
Fujisaki Seiichiro, Takashita Emi, Yokoyama Masaru, Taniwaki Tae, Xu Hong, Kishida Noriko, Sato Hironori, Tashiro Masato, Imai Masaki, Odagiri Takato
Abstract excerpt
Drugs inhibiting the enzymatic activity of influenza virus neuraminidase (NA) are the cornerstone of therapy for influenza virus infection. The emergence of drug-resistant variants may limit the benefits of antiviral therapy. Here we report the recovery of an influenza B virus with reduced susceptibilities to NA inhibitors from a human patient with no history of antiviral drug treatment. The virus, designated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.